



## ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

### 宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

#### Proxy Form for the Annual General Meeting to be held on May 28, 2025

I/We <sup>(Note 1)</sup> \_\_\_\_\_  
of \_\_\_\_\_

being the registered holder(s) of \_\_\_\_\_ H share(s)/Unlisted  
share(s) <sup>(Note 2)</sup> (the "Shares") of RMB1.00 each of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "Company") hereby appoint **the Chairman of the annual general meeting** (the "Meeting") of the Company or <sup>(Note 1)</sup> \_\_\_\_\_

of \_\_\_\_\_  
as my/our proxy to attend and act for me/us at the Meeting of the Company to be held at Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, PRC on May 28, 2025 at 9:30 a.m. or any adjournment thereof, for the purpose of considering and if thought fit, passing the resolutions set out in the notice convening the Meeting, and to vote on behalf of me/us under my/our name as indicated below <sup>(Note 4)</sup> in respect of the resolutions to be proposed at the Meeting and any of its adjournment <sup>(Note 4)</sup>.

Unless otherwise indicated, capitalized terms used herein shall have the same meaning as those defined in the circular of the Company dated April 30, 2025.

ORDINARY RESOLUTIONS		FOR <sup>(Note 4)</sup>	AGAINST <sup>(Note 4)</sup>
1.	To consider and approve the work report of the Board of Directors of the Company (the "Board") for the year 2024.		
2.	To consider and approve the work report of the supervisory committee of the Company (the "Supervisory Committee") for the year 2024.		
3.	To consider and approve the annual report of the Company for the year 2024.		
4.	To consider and approve the final financial report of the Company for the year 2024 and the financial budget report of the Company for the year 2025.		
5.	To consider and approve the 2024 Profit Distribution Plan.		
6a.	To consider and approve the appointment of Mr. Zhang Ruliang as an executive Director of the Company with the term of office, upon approval at the Annual General Meeting and ending upon the expiry of the term of appointment of the second session of the Board.		
6b.	To consider and approve the appointment of Ms. Fu Dawei as a non-executive Director of the Company with the term of office, upon approval at the Annual General Meeting and ending upon the expiry of the term of appointment of the second session of the Board.		
6c.	To consider and approve the re-election of Dr. Tian Wenzhi as executive Director of the second session of the Board.		
6d.	To consider and approve the re-election of Mr. Li Song as executive Director of the second session of the Board.		
6e.	To consider and approve the re-election of Ms. Guan Mei as executive Director of the second session of the Board.		
6f.	To consider and approve the re-election of Dr. Xu Cong as non-executive Director of the second session of the Board.		
6g.	To consider and approve the re-election of Dr. Zhenping Zhu as independent non-executive Director of the second session of the Board.		
6h.	To consider and approve the re-election of Dr. Kendall Arthur Smith as independent non-executive Director of the second session of the Board.		
6i.	To consider and approve the re-election of Mr. Yeung Chi Tat as independent non-executive Director of the second session of the Board.		
7.	To consider and approve the re-election of Ms. Tian Miao as a shareholder representative Supervisor of the second session of the Supervisory Committee.		
8.	To consider and approve the re-appointment of Deloitte Touche Tohmatsu as the auditor of the Company for the year 2025 and to authorise the Board to determine its remuneration.		
9.	To consider and approve the directors remuneration plan for the year 2025.		
10.	To consider and approve the supervisors remuneration plan for the year 2025.		
11.	To consider and approve the proposed change in use of proceeds.		

SPECIAL RESOLUTION		FOR <sup>(Note 4)</sup>	AGAINST <sup>(Note 4)</sup>
12.	To consider and approve granting of a general mandate to the Board to exercise the right to allot, issue and/or deal with new shares of the Company.		
13.	To consider and approve the proposed grant of general mandate to the Board to repurchase H Shares.		

Signature <sup>(note 3)</sup> \_\_\_\_\_

Date <sup>(note 3)</sup> \_\_\_\_\_

**Notes:**

1. If any proxy other than the chairman of the meeting is preferred, please insert the full name and address of the proxy desired in the space provided. A holder entitled to attend and vote at the meeting of the Company is entitled to appoint one or more proxies to attend and vote on his/her behalf. **ANY ALTERATION MADE TO THIS PROXY FORM MUST BE INITIALED BY THE PERSON WHO SIGNS IT.** The proxy needs not be a member of the Company, but must attend the meeting (or any adjournment thereof) to represent you.
2. Please insert the number of shares for this proxy and delete as appropriate. If no number is inserted, this proxy form will be deemed to relate to all the shares registered in the name of the holder(s).
3. This proxy form must be signed and dated by the shareholder or his/her attorney duly authorised in writing. If the shareholder is a company, it should execute this proxy form under its common seal or by the signature(s) of (a) person(s) authorised to sign on its behalf. In the case of joint shareholders, any one shareholder may sign this proxy form. The vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose seniority will be determined by the order in which the names stand in the register of members in respect of the joint shareholding.
4. **IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, TICK (✓) IN THE RELEVANT BOX BELOW MARKED “FOR”. IF YOU WISH TO VOTE AGAINST A RESOLUTION, TICK (✓) IN THE RELEVANT BOX BELOW MARKED “AGAINST”.** Failure to tick either box in respect of a resolution will entitle your proxy to cast your vote in respect of that resolution at his/her discretion or to abstain. Your proxy will also be entitled to vote at his/her discretion or to abstain on any resolution properly put to the meeting other than those referred to in the notice convening the meeting.
5. This form of proxy must be signed by you or your attorney duly authorised in writing. In case of a corporation, the same must be executed either under its common seal or under the hand of its director or an attorney duly authorised to sign the same.
6. In order to be valid, a proxy form and the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy of such power of attorney, must be deposited at the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares), or the Company's head office and principal place of business in the PRC, at Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, PRC (for holders of Unlisted Shares), not less than 24 hours before the time fixed for holding the meeting or any adjournment thereof.
7. Completion and delivery of this proxy form will not preclude you from attending and voting at the meeting if you so wish.
8. Please provide one certificate number, if possible, to facilitate processing.
9. For the avoidance of doubt, we do not accept any special instructions written on this proxy form.
10. The above description of the proposed ordinary and special resolutions is by way of summary only. The full text appears in the notice of the Annual General Meeting.